{"id":236386,"date":"2026-09-09T10:55:14","date_gmt":"2026-09-09T05:25:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=236386"},"modified":"2026-09-09T10:55:14","modified_gmt":"2026-09-09T05:25:14","slug":"alivus-life-sciences-q2-results-fy27-preview-date-expectations-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/","title":{"rendered":"Alivus Life Sciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Alivus Life Sciences share price Rs 1,416.20 on 9 September 2026, up 3.22%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 160.00 crore. Q2 FY26 base a profit of Rs 130.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Alivus Life Sciences Q2 results date for FY27 is not confirmed, and Alivus Life Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 588.00 crore in revenue and a profit of Rs 130.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Alivus Life Sciences Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/alivus\/glenmark-life-sciences-ltd-share-price-today\">Alivus Life Sciences Ltd.<\/a>, an active pharmaceutical ingredients maker, formerly listed as Glenmark Life Sciences, supplying regulated and emerging markets alongside a contract development and manufacturing business. The stock traded at Rs 1,416.20 on the NSE on 9 September 2026, up 3.22% from the previous close of Rs 1,372.00, about 5.2% below its 52-week high of Rs 1,493.80 and 72.9% above its 52-week low of Rs 819.00.<\/p>\n<p>What makes the Alivus Life Sciences Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 588.00 crore of revenue and a profit of Rs 130.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 640.00 crore and a profit of Rs 160.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=alivus_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#When_Is_the_Alivus_Life_Sciences_Q2_Results_FY27_Date\" title=\"When Is the Alivus Life Sciences Q2 Results FY27 Date?\">When Is the Alivus Life Sciences Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Alivus_Life_Sciences_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Alivus Life Sciences Q2 Results Expectations: What the Market Is Actually Tracking\">Alivus Life Sciences Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Alivus_Life_Sciences_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Alivus Life Sciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Alivus Life Sciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Q2_FY26_Base_The_Comparison_Alivus_Life_Sciences_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Alivus Life Sciences Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Alivus Life Sciences Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Alivus_Life_Sciences_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Alivus Life Sciences Quarterly Results Trend Over the Last Four Quarters\">Alivus Life Sciences Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Key_Factors_That_Could_Shape_Alivus_Life_Sciences_Q2_Results_FY27\" title=\"Key Factors That Could Shape Alivus Life Sciences Q2 Results FY27\">Key Factors That Could Shape Alivus Life Sciences Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Regulated_Market_Supply\" title=\"Regulated Market Supply\">Regulated Market Supply<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Name_Change_From_Glenmark_Life_Sciences\" title=\"Name Change From Glenmark Life Sciences\">Name Change From Glenmark Life Sciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Strong_Returns_and_a_Strong_Run\" title=\"Strong Returns and a Strong Run\">Strong Returns and a Strong Run<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Alivus_Life_Sciences_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Alivus Life Sciences Q2 Results FY27: Share Price and Valuation Going Into the Print\">Alivus Life Sciences Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#What_Investors_Should_Watch_When_Alivus_Life_Sciences_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Alivus Life Sciences Q2 Results Are Announced\">What Investors Should Watch When Alivus Life Sciences Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Conclusion_on_Alivus_Life_Sciences_Q2_Results_FY27\" title=\"Conclusion on Alivus Life Sciences Q2 Results FY27\">Conclusion on Alivus Life Sciences Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#FAQs_on_Alivus_Life_Sciences_Q2_Results_FY27\" title=\"FAQs on Alivus Life Sciences Q2 Results FY27\">FAQs on Alivus Life Sciences Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#What_is_the_Alivus_Life_Sciences_Q2_results_date_for_FY27\" title=\"What is the Alivus Life Sciences Q2 results date for FY27?\">What is the Alivus Life Sciences Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#What_quarter_do_the_Alivus_Life_Sciences_Q2_results_2026_cover\" title=\"What quarter do the Alivus Life Sciences Q2 results 2026 cover?\">What quarter do the Alivus Life Sciences Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#What_were_the_Alivus_Life_Sciences_Q1_FY27_results\" title=\"What were the Alivus Life Sciences Q1 FY27 results?\">What were the Alivus Life Sciences Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#What_were_Alivus_Life_Sciences_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Alivus Life Sciences Q2 FY26 results in the September 2025 quarter?\">What were Alivus Life Sciences Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#What_are_the_main_Alivus_Life_Sciences_Q2_results_expectations_this_quarter\" title=\"What are the main Alivus Life Sciences Q2 results expectations this quarter?\">What are the main Alivus Life Sciences Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#What_is_Alivus_Life_Sciences_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Alivus Life Sciences share price today ahead of the Q2 earnings?\">What is Alivus Life Sciences share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-2\/#Is_Alivus_Life_Sciences_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Alivus Life Sciences a good stock to buy before the Q2 results?\">Is Alivus Life Sciences a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Alivus_Life_Sciences_Q2_Results_FY27_Date\"><\/span><strong>When Is the Alivus Life Sciences Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Alivus Life Sciences Q2 results date for FY27 is not confirmed. As of 9 September 2026, Alivus Life Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Alivus Life Sciences Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p>The Alivus Life Sciences Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Alivus Life Sciences.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Alivus Life Sciences Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Alivus Life Sciences Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Alivus Life Sciences. The Alivus Life Sciences Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>The first is the steady margin improvement. Operating margin reached 33% in Q1 FY27 against 30% in the September 2025 quarter, and that has carried profit from Rs 130 crore to Rs 160 crore even though revenue was slightly higher rather than dramatically so.<\/p>\n<p>The second is the active ingredients order pattern. Supply to regulated market customers arrives in campaigns, which is why revenue moved between Rs 588 crore and Rs 689 crore across five quarters without a clear trend.<\/p>\n<p>The third is the contract development and manufacturing business. That segment carries different economics from the base active ingredients portfolio, and its growth is what would lift margin structurally rather than cyclically.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Alivus Life Sciences Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Alivus Life Sciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences Ltd. reported revenue of Rs 640.00 crore in Q1 FY27, up 6.31% from Rs 602.00 crore in Q1 FY26, and a profit of Rs 160.00 crore at the net level, up 31.15% from Rs 122.00 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p>Sequentially, revenue was down 7.11% over the March 2026 quarter figure of Rs 689.00 crore, and net profit was down 1.84% from Rs 163.00 crore in Q4 FY26. Operating margin stood at 33.0% in Q1 FY27 against 30.0% in the September 2025 quarter, which is the comparison the Alivus Life Sciences Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Alivus_Life_Sciences_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Alivus Life Sciences Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences Ltd. reported revenue of Rs 588.00 crore and a profit of Rs 130.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Alivus Life Sciences Q2 results preview.<\/p>\n<p>Net profit in that base quarter was below the Rs 160.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 588.00 crore sits below the Rs 640.00 crore of the June 2026 quarter, which frames how much sequential movement the Alivus Life Sciences Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Alivus Life Sciences Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>588.00<\/td>\n<td>130.00<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>673.00<\/td>\n<td>150.00<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>689.00<\/td>\n<td>163.00<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>640.00<\/td>\n<td>160.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Alivus Life Sciences Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 588.00 crore to Rs 689.00 crore, and net profit from Rs 130.00 crore to Rs 163.00 crore. That spread is the honest context for the Alivus Life Sciences Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Alivus_Life_Sciences_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Alivus Life Sciences Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Alivus Life Sciences Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Alivus Life Sciences has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulated_Market_Supply\"><\/span><strong>Regulated Market Supply<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Selling active ingredients into regulated markets requires plant approvals and customer qualification. Any inspection outcome disclosed with results affects the addressable revenue for several quarters ahead.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Name_Change_From_Glenmark_Life_Sciences\"><\/span><strong>Name Change From Glenmark Life Sciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The company was formerly listed as Glenmark Life Sciences and several data sources still carry that name. Figures for the same period can appear under either label, which matters when comparing across sources.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Strong_Returns_and_a_Strong_Run\"><\/span><strong>Strong Returns and a Strong Run<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Alivus Life Sciences generates a return on equity of 17.90% with a debt-to-equity ratio of 0.12, and trades at a price-to-earnings ratio of 27.96 against a sector average of 37.99. The stock has risen from a 52-week low of Rs 819.00 to near its high of Rs 1,493.80.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Alivus Life Sciences Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences share price today is Rs 1,416.20 on the NSE, up Rs 44.20 or 3.22% from the previous close of Rs 1,372.00 on 9 September 2026, ahead of the Alivus Life Sciences Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (8 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>ALIVUS<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 1,416.20<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 1,493.80<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 819.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 16,863 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>27.96<\/td>\n<\/tr>\n<tr>\n<td>Sector PE<\/td>\n<td>37.99<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>5.22<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 50.65<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 271.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.12<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>17.90%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 1,267.70<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 1,045.84<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>56.64<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above both its 50-day average of Rs 1,267.70 and its 200-day average of Rs 1,045.84, with a 14-day RSI of 56.64. None of this is a view on where the shares go once the Alivus Life Sciences Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Alivus Life Sciences Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Alivus_Life_Sciences_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Alivus Life Sciences Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Alivus Life Sciences Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 588.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 130.00 crore in that same quarter<\/li>\n<li>Operating margin against 33.0% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Alivus Life Sciences Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Alivus_Life_Sciences_Q2_Results_FY27\"><\/span><strong>Conclusion on Alivus Life Sciences Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Alivus Life Sciences Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Alivus Life Sciences Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Alivus Life Sciences Q2 results FY27 print faces a base of Rs 588.00 crore in revenue and a profit of Rs 130.00 crore, with the most recent quarter having delivered Rs 640.00 crore and a profit of Rs 160.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Alivus Life Sciences, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Alivus_Life_Sciences_Q2_Results_FY27\"><\/span><strong>FAQs on Alivus Life Sciences Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alivus_Life_Sciences_Q2_results_date_for_FY27\"><\/span><strong>What is the Alivus Life Sciences Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Alivus Life Sciences Q2 results date for FY27 is not confirmed. Alivus Life Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Alivus_Life_Sciences_Q2_results_2026_cover\"><\/span><strong>What quarter do the Alivus Life Sciences Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Alivus Life Sciences Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Alivus Life Sciences Ltd. reports revenue, operating profit and net profit for that period, and the Alivus Life Sciences Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Alivus_Life_Sciences_Q1_FY27_results\"><\/span><strong>What were the Alivus Life Sciences Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences Ltd. reported revenue of Rs 640.00 crore in Q1 FY27 and a profit of Rs 160.00 crore at the net level. Revenue was up 6.31% versus Q1 FY26 and net profit was up 31.15% from Rs 122.00 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Alivus_Life_Sciences_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Alivus Life Sciences Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences Ltd. reported revenue of Rs 588.00 crore and a profit of Rs 130.00 crore in Q2 FY26. Operating margin was 30.0%. Those figures form the base for the Alivus Life Sciences Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Alivus_Life_Sciences_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Alivus Life Sciences Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Alivus Life Sciences Q2 results expectations centre on revenue against the Rs 588.00 crore base, net profit against a profit of Rs 130.00 crore, operating margin against 33.0% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Alivus_Life_Sciences_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Alivus Life Sciences share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences share price is Rs 1,416.20 on the NSE as of 9 September 2026, up 3.22% from Rs 1,372.00. The stock is about 5.2% below its 52-week high of Rs 1,493.80 and 72.9% above its 52-week low of Rs 819.00, at a market capitalisation of Rs 16,863 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alivus_Life_Sciences_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Alivus Life Sciences a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Alivus Life Sciences Ltd.. The stock trades at a price-to-book ratio of 5.22 with a return on equity of 17.90%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alivus Life Sciences Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Alivus Life Sciences Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":236385,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-236386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["236385"],"rank_math_title":["Alivus Life Sciences Q2 Results FY27: Date and View"],"rank_math_description":["Alivus Life Sciences Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Alivus Life Sciences Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/alivus-life-sciences-q2-results-fy27-preview-date-expectations-1.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=236386"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236386\/revisions"}],"predecessor-version":[{"id":236387,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236386\/revisions\/236387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/236385"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=236386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=236386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=236386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}